Adaptive NGS MRD Feature

Discover the next-generation of MRD assessment
Gain insights into the science of molecular testing and its potential

Discover the next-generation of MRD assessment

Gain insights into the science of molecular testing and its potential

Applying NGS and MRD assessment in the clinic

Jeffrey Wolf, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, reflects on the advantages of next-generation sequencing (NGS) as a specific way to assess measurable residual disease (MRD).

Understanding MRD in myeloma and ALL

Katja Weisel, MD, from University Hospital Tubingen, Tubingen, Germany explains the concept of MRD and its importance as a parameter when evaluating clinical response. As novel therapies that produce deep clinical responses are being prescribed for lymphoid malignancies, new ways to measure disease outcomes are needed.

Measuring MRD: NGS vs. flow cytometry

Prof. Weisel discusses the similarities and differences between using NGS and flow cytometry, the two predominant methods of measuring MRD. Both methods involve obtaining a bone marrow sample. Among the main differences between the two methods are the sensitivity and the intrinsically standardized nature of NGS-based MRD assays compared with flow cytometry.

clonoSEQ®: FDA-cleared for myeloma and B-ALL

Lanny Kirsch, MD, SVP Translational Medicine, Adaptive Biotechnologies, explains how clonoSEQ detects MRD and highlights the importance of the recognition of assays such as this by regulatory agencies as important tools for the treatment of patients with lymphoid malignancies.

Skip to toolbar